Results 181 to 190 of about 5,853,531 (371)
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald+18 more
wiley +1 more source
Clarifying the Gateway Hypothesis and Conflict of Interest in Cannabis Research. [PDF]
Shiraishi K.
europepmc +1 more source
Conflict of Interest and Plastic Surgery Journal Editors: The Problem and the Solution. [PDF]
Swanson E.
europepmc +1 more source
Journal Policies on Conflict of Interest: If this Is the Therapy, What’s the Disease? [PDF]
Sheldon Krimsky
openalex +1 more source
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias+12 more
wiley +1 more source
Public trust requires disclosure of potential conflicts of interest [PDF]
Steven Gurney, Jennifer Sass
openalex +1 more source
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley +1 more source
Conflict of Interest in Medicine.
Christopher C. Muth
semanticscholar +1 more source